Influence of aging and comorbidity in the choice of disease-modifying treatments for multiple sclerosis in the Lazio region

被引：0

作者：

Pozzilli, C. ^{[1
,2
]}

Gasperini, C. ^{[3
]}

Bargagli, A. M. ^{[4
]}

Cascini, S. ^{[4
]}

Buttari, F. ^{[5
,6
]}

Centonze, D. ^{[5
,6
]}

Di Folco, M. ^{[1
]}

Francia, A. ^{[1
]}

Galgani, S. ^{[3
]}

Giuliani, M. ^{[2
]}

Colais, P. ^{[4
]}

Mirabella, M. ^{[7
]}

Nociti, V. ^{[7
,8
]}

Davoli, M. ^{[4
]}

机构：

[1] Univ Roma La Sapienza, Dept Neurol & Psichiatry, Rome, Italy

[2] Univ Roma La Sapienza, Multiple Sclerosis Ctr, S Andrea Hosp, Rome, Italy

[3] AOS Camillo Forlanini, Dept Neurosci, Rome, Italy

[4] Lazio Reg Hlth Serv, Dept Epidemiol, Rome, Italy

[5] Tor Vergata Univ & Hosp, MS Clin & Res Ctr, Rome, Italy

[6] IRCCS Ist Neurol Mediterraneo INM Neuromed, Pozzilli, Italy

[7] Catholic Univ, Dept Geriatr Neurosci & Orthoped, Rome, Italy

[8] Fdn Don C Gnocchi, Inst Neurorehabil, Milan, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EP1478

引用

页码：771 / 772

页数：2

共 50 条

[21] Can we discontinue disease-modifying treatments in multiple sclerosis patients? No
Papeix, C.
REVUE NEUROLOGIQUE, 2017, 173 (1-2) : 41 - 43
[22] Oral disease-modifying treatments for multiple sclerosis - The story so far
Kieseier, Bernd C.
Wiendl, Heinz
CNS DRUGS, 2007, 21 (06) : 483 - 502
[23] The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis
Brown, J. W. L.
Coles, A.
Horakova, D.
Havrdova, E.
Trojano, M.
Izquierdo, G.
Prat, A.
Girard, M.
Hupperts, R.
Van Pesch, V.
Ferraro, D.
Alroughani, R.
Bergamaschi, R.
Pucci, E.
Iuliano, G.
Lechner-Scott, J.
Spelman, T.
Jokubaitis, V.
Ramo-Tello, C.
Spitaleri, D.
Granella, F.
Solaro, C.
Ampapa, R.
Deri, N.
McCombe, P.
Petersen, T.
Van Wijmeersch, B.
Prevost, J.
Sanchez-Menoyo, J. L.
Soysal, A.
Barnett, M.
Moore, F.
Rice, C.
Scolding, N.
Wilkins, A.
McGuigan, C.
Hutchinson, M.
Ziemssen, T.
Pearson, O.
Harding, K.
Duquette, P.
Lugaresi, A.
Grammond, P.
Grand'Maison, F.
Terzi, M.
Shaygannejad, V.
Sola, P.
Butzkueven, H.
Kalincik, T.
Robsertson, N.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 32 - 34
[24] Discontinuation Of Prolonged Disease-modifying Treatments In Multiple Sclerosis: A Difficult Decision
Tuncer, A.
Ozen, P. Acar
Karabudak, R.
MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 65 - 65
[25] Established disease-modifying treatments in relapsing-remitting multiple sclerosis
Oh, Jiwon
O'Connor, Paul W.
CURRENT OPINION IN NEUROLOGY, 2015, 28 (03) : 220 - 229
[26] Comorbidity and persistence of disease-modifying therapy use in relapsing remitting multiple sclerosis
Parks, Natalie E.
Andreou, Pantelis
Marrie, Ruth Ann
Fisk, John
Bhan, Virender
Kirkland, Susan A.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 56
[27] Factors that influence adherence with disease-modifying therapy in multiple sclerosis
Treadaway, KD
Brannon, KD
Morrison, A
Remington, GM
Olek, M
Racke, MK
Frohman, EM
NEUROLOGY, 2006, 66 (05) : A30 - A30
[28] Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
Simone, Isabella Laura
Tortorella, Carla
Ghirelli, Alma
FRONTIERS IN NEUROLOGY, 2021, 12
[29] Factors that influence adherence with disease-modifying therapy in multiple sclerosis
Treadaway, K
Hawker, K
Racke, M
Brannon, K
Morrison, A
Remington, G
Frohman, E
Cohen, B
Corboy, J
Simsarian, J
Lynch, S
Jeffery, D
MULTIPLE SCLEROSIS, 2005, 11 : S158 - S158
[30] Disease-modifying therapies for multiple sclerosis
De Angelis, Floriana
John, Nevin A.
Brownlee, Wallace J.
BMJ-BRITISH MEDICAL JOURNAL, 2018, 363

← 1 2 3 4 5 →